

# VENABLE | Fitzpatrick



March 12, 2020

# in y f 🏞

#### LATEST NEWS



## FDA Updates Relating to Biosimilars

February was a busy month for the FDA in the field of biosimilars:

On February 3, 2020, the FDA and FTC issued a joint statement regarding their enhanced collaboration to support the adoption of biosimilars and interchangeables.

On February 3, 2020, the FDA published a draft guidance, "<u>Promotional</u> <u>Labeling and Advertising Considerations for Prescription Biological</u>

<u>Reference and Biosimilar Products Questions and Answers</u>." Comments will be accepted until April 2, 2020.

- On February 3, 2020, the FDA and FTC <u>announced a public workshop</u> on a competitive marketplace for biosimilars, to take place on March 9, 2020.
- On February 6, 2020, the FDA issued a draft guidance, "<u>Biosimilars and Interchangeable Biosimilars:</u> <u>Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed</u>." Comments will be accepted until April 6, 2020.
- On February 21, 2020, a <u>final rule</u> on the definition of "biological product" was published. This rule defines "protein" as "any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size." The FDA is using this "bright line" approach to reduce uncertainty regarding whether products will be regulated as drugs or biological products. Under the final definition, "insulin clearly is a 'protein' ... because the total number of amino acids exceeds 40" and thus will be regulated as a biological product.
- On February 21, 2020, the FDA issued frequently asked question documents for <u>patients</u> and <u>health care</u> <u>providers</u> relating to the transition of biological products approved under the Food, Drug, and Cosmetic Act, such as insulin and human growth hormone, from being regulated as drugs to being regulated as biological products, as of March 23, 2020.
- On February 24, 2020, the FDA launched its revised version of the "Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations," also known as the <u>Purple Book</u>, that is now searchable. This initial phase of the searchable database includes information on licensed biosimilar and interchangeable products and their reference products.



<u>Spotlight On: Herceptin<sup>®</sup> (trastuzumab) / Ogivri™</u> (trastuzumab-dkst) / Herzuma<sup>®</sup> (trastuzumab-pkrb) / Ontruzant<sup>®</sup> (trastuzumab-dttb) / Trazimera™ (trastuzumabqyyp) / Kanjinti™ (trastuzumab-anns)

Spotlight On: Biosimilar Litigations

<u>Spotlight On: Rituxan<sup>®</sup> (rituximab) / Truxima<sup>®</sup> (rituximab-</u>

## <u>abbs) / Ruxience<sup>®</sup> (rituximab-pvvr)</u>

<u>Spotlight On: Humira<sup>®</sup> (adalimumab) / Amjevita™ (adalimumab-atto) / Cyltezo<sup>®</sup> (adalimumab-adbm) / Hyrimoz™ (adalimumab-adaz) / Hadlima™ (adalimumab-bwwd) / Abrilada™ (adalimumab-afzb)</u>

<u>Spotlight On: Enbrel<sup>®</sup> (etanercept) / Erelzi<sup>®</sup> (etanercept-szzs) / Eticovo™ (etanerceptykro)</u>

<u>Spotlight On: Lantus<sup>®</sup> / Lantus<sup>®</sup> SoloSTAR<sup>®</sup> (insulin glargine recombinant) / Basaglar<sup>®</sup> (insulin glargine)</u>

BiologicsHQ's "Spotlight On" product dashboards provide, at a glance, an overview of the status of U.S. patent proceedings. The dashboards concerning trastuzumab (<u>Herceptin<sup>®</sup></u>, <u>Ogivri™</u>, <u>Herzuma<sup>®</sup></u>, <u>Ontruzant<sup>®</sup></u>, <u>Trazimera™</u>, and <u>Kanjinti™</u>), rituximab (<u>Rituxan<sup>®</sup></u>, <u>Truxima<sup>®</sup></u>, and <u>Ruxience<sup>®</sup></u>), adalimumab (<u>Humira<sup>®</sup></u>, <u>Amjevita™</u>, <u>Cyltezo<sup>®</sup></u>, <u>Hyrimoz™</u>, <u>Hadlima™</u>, and <u>Abrilada™</u>), etanercept (<u>Enbrel<sup>®</sup></u>, <u>Erelzi<sup>®</sup></u>, and <u>Eticovo™</u>), and insulin glargine (<u>Lantus<sup>®</sup> / Lantus<sup>®</sup> SoloSTAR<sup>®</sup></u> and <u>Basaglar<sup>®</sup></u>) have been updated with activity through February 29, 2020.

BiologicsHQ's "Spotlight On Biosimilar Litigations" dashboard provides, at a glance, an overview of the status of U.S. biosimilar patent litigations through February 29, 2020.



## **UPDATES**

## **IPRs and PGRs**

## <u>Myozyme<sup>®</sup> / Lumizyme<sup>®</sup> (alglucosidase alfa)</u>:

• On February 3, 2020, the Federal Circuit denied Duke University's request for en banc rehearing of its decision in Federal Circuit Case No. 18-1696, affirming the PTAB's obviousness decision on remand of IPR2013-00535.

## Lantus<sup>®</sup> (insulin glargine recombinant):

• On February 6, 2020, the Federal Circuit denied <u>Sanofi's</u> motion to stay its mandate pending a forthcoming Supreme Court writ of certiorari in consolidated Federal Circuit Case Nos. 19-1368 and 19-1369, appealing the final written decisions in IPR2017-01526 and IPR2017-01528.

 On February 10, 2020, in Case No. 19A886, the Supreme Court issued an order staying the issuance of the Federal Circuit's mandate in consolidated Federal Circuit Case Nos. 19-1368 and 19-1369. On February 14, 2020, the Supreme Court vacated its order and denied <u>Sanofi's</u> application for a stay pending a Supreme Court decision on a forthcoming writ of certiorari.

#### <u>Ajovy<sup>®</sup> (fremanezumab-vfrm) / Emgality<sup>®</sup> (galcanezumab-gnlm):</u>

On February 18, 2020, the PTAB issued final written decisions in <u>*Eli Lilly v. Teva*</u> IPR2018-01422, IPR2018-01423, IPR2018-01424, IPR2018-01425, IPR2018-01426, and IPR2018-01427 finding all instituted claims unpatentable.

#### <u>Taltz<sup>®</sup> (ixekizumab)</u>:

 On February 24, 2020, <u>Genentech</u> filed requests for adverse judgment after institution in PGR2019-00043, filed by <u>Eli Lilly</u>, and PGR2019-00044, filed by <u>UCB</u> on the same patent.

## Litigations

#### <u>Neulasta<sup>®</sup> (pegfilgrastim)</u>:

On February 11, 2020, <u>Amgen</u> filed Case No. 1:20-cv-00201 (D. Del.) against <u>Hospira</u> and <u>Pfizer</u> related to their proposed biosimilar <u>PF-06881894</u>.

#### <u>Taltz<sup>®</sup> (ixekizumab)</u>:

• On February 26, 2020, Genentech filed a motion to voluntarily dismiss Case No. 3:18-cv-01518 (S.D. Cal.).

## aBLA Applications and FDA Activity

#### FYB201 (ranibizumab):

On February 4, 2020, <u>Formycon</u> and <u>Bioeq</u> announced that they withdrew their aBLA for <u>FYB201</u>
<u>(ranibizumab)</u>, a proposed biosimilar of <u>Genentech's Lucentis® (ranibizumab)</u>, after the FDA requested additional data. They plan to resubmit the application after providing the requested data.

#### <u>Trazimera™ (trastuzumab-qyyp)</u>:

 On February 15, 2020, <u>Pfizer</u> launched <u>Trazimera™ (trastuzumab-qyyp)</u>, a biosimilar of <u>Genentech's</u> <u>Herceptin<sup>®</sup> (trastuzumab)</u>, at a 22% discount.

## **CDER Purple Book Updates**

#### <u>Vyepti™ (eptinezumab-jjmr)</u>:

• On February 21, 2020, the FDA approved <u>Lundbeck Seattle BioPharmaceuticals'</u> <u>Vyepti™ (eptinezumab-jjmr)</u>.

#### Non-U.S. Biosimilars / Follow-On Biologics

#### <u>Amsparity™ (adalimumab)</u>:

On February 13, 2020, <u>Pfizer's Amsparity™ (adalimumab)</u>, a biosimilar of <u>AbbVie's Humira<sup>®</sup> (adalimumab)</u> was approved in the E.U.

## **STATISTICS**

Biosimilar-Related IPR Petitions



Biosimilar-Related IPRs by Reference <u>Product</u>



Biosimilar-Related IPRs: Institution and Final Written Decision Outcomes



Biosimilar-Related Litigations by Year



**Biosimilar Applications** 

#### Biosimilar-Related IPR Petitions by Fiscal Year



Biosimilar-Related IPRs: Number of Patents and Claims Challenged

	Related IPRs: nts & Claims Challenged
-	
55 Patents	1702" Claims Challenged
MEXILE   Filopotrick	These is the experimental section of the testing the section of the section of the testing of the testing and the section of the section of the section of the section of the section of the section of the testing of the section of the section of the section of the testing of the section of t

<u>Biosimilar-</u> <u>Related</u> <u>Litigations</u>



Patents Subject to Biosimilar-Related IPRs and Litigations



Biologic Drug

#### Biosimilar-Related IPR Petitions by Quarter



<u>Status of</u> <u>Biosimilar-</u> <u>Related IPRs</u>



Biosimilar-Related Litigations by Reference Product



Biosimilars Approved in the United States

AQ United States								
- <u>1</u>	Rosseller Dense Rosse	Real Provided in the local division of the l	-	Annal Marcaler Marcaler	****** *****	Andrease Andrease Ballet	-	
10.0	Admin'	Addressed who	Array of	0m (0.014	Hantal	ingitized and in the second		
10.0	Odear	ANDUNE	Russian I	A4 (8.977	10000	100 million		
ARK.	"pines"	Allingth	Domini 1	04.01.018	10000	NUCL.		
10.0	index."	Alternativ	Service .	ALC: 174	10000	10116		
100	Autor"	-	(Rev)	No. 11, 275	10000	NUCL.		
ARK.	tear.	In a long	Anges	10.001	August 1	Caracterio III.	ALT	
100	Dian"	feminet-	1944	10.17.270	inger .	Caracterio I	04.27	
100	Name 7	Eastern Ministern	House Print	89, 11, 210	tpoper.	regar.	100.00	
ALC: NO	8447	Environments	Table .	44.00.000	Eller?	TAXABLE INSPECT		
224	these.	Environment of the	Concession in the local division in the loca	41.01.018	Ellevit.	TAXABLE (TRAFT)		
355	Chest.	PERSONAL PROPERTY AND INC.	Table .	10.0.000	Name of	ingen.	-	
324	Summer of	Inguest and	inger .	ALC: UNK	No. of Concert	angen.	-	

Biologic Drug

#### Pending in the United States

	Longia Same	ett. a. tit Notal T	Robusso Redat	Particular Annual Listing	Fiches
188	Rouge Land	forming fromth	1.447	Terenal I	Arrested New Jorney
Doct-T	<b>Ageda</b>	Name and Addressor	(approx)	(August)	Accepted Fair (2015)
	1940	(former), have	tagget*	ange:	Anaplet Say, 2017
1940	199804	Tenes Dufferent	teoport.	Auger 1	Accepted Net 2018 Complete Perspective Linter Net 24
Lawy	<b>Surgests</b>	Applies	Second P	diagon.	Accepted that 2014 Accepted from 2018
-	hyppads.	that the	Takarat <sup>a</sup>	inger .	Appropriate and and a
10000	Profilements	Pare	Red and all	the gent	Accepted Ings (2010)
PH001	Retinent	Fample (Born)	inerts"	-lewise	Recent fail 2012
Realizer	Anamat	famile	Prost 1	-	Anapolit Res 2014 URL Res 2018 Service on insper provide URL Restored URL REST
107-766	Anamat	Argen (Airspo)	Pear	Contract of Contra	Gambrid On: 2018
Lating "	Institution	Beat.	Lanua"	<b>Description</b>	Telative Approval ALCONT
Distant in the local distance in the local d	Institution	N/M House	Later 1	Institutio	176. Jan 2010

Patents Subject to Biologic Drug IPRs and Litigations



IPR Petitions



Biologic Drugs Most Frequently Targeted in Serial IPR Challenges



#### <u>Number of IPR</u> <u>Challenges Per</u> <u>Biologic Drug Patent</u>







#### Biologic Drug Patent Multiple IPR Challenges by Claim Type





## Contact the BiologicsHQ Team







Ha Kung Wong Partner +1 212.218.2571 HWong@Venable.com

#### CALIFORNIA | DELAWARE | MARYLAND | NEW YORK | VIRGINIA | WASHINGTON, DC

© 2020 Venable LLP. This email is published by the law firm Venable LLP. It is not intended to provide legal advice or opinion. Such advice may only be given when related to specific fact situations that Venable has accepted an engagement as counsel to address. ATTORNEY ADVERTISING.

Venable.com | Manage Preferences | Unsubscribe | If you are having trouble viewing this email, click here to view it in the browser or contact us by mail at Venable LLP, 600 Massachusetts Avenue, NW, Washington, DC 20001.